August 18, 2022
Forxiga (dapagliflozin) became the top-selling diabetes drug in Japan in April-June, according to data released by IQVIA on August 17. The SGLT2 inhibitor snapped the winning streak of the DPP-4 inhibitor Januvia (sitagliptin) for the first time in 11 years...read more